Mark Freedman

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

Paul O’Connor, Jerry S. Wolinsky, Christian Confavreux et al. · New England Journal of Medicine · 2011 · 965 citations · Full text

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

Christian Confavreux, Paul O’Connor, Mark Freedman et al. · The Lancet Neurology · 2014 · 566 citations

Oral Teriflunomide, Neurological Disorder, Medicine +6

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

Patrick Vermersch, Anna Członkowska, Luigi ME Grimaldi et al. · Multiple Sclerosis Journal · 2013 · 348 citations · Full text

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

Aaron Miller, Jerry S. Wolinsky, Ludwig Kappos et al. · The Lancet Neurology · 2014 · 295 citations

Oral Teriflunomide, Neurological Disorder, Symptomatic Treatment +5